Lupin Faces USFDA Form 483 Issuance Amid Somerset Facility Compliance Scrutiny
Major pharmaceutical company Lupin has confirmed that a regulatory filing revealed the US Food and Drug Administration (USFDA) issued a 'Form 483' carrying three observations regarding its manufacturing facility in Somerset, New Jersey. The findings follow a recent inspection conducted by the US health regulator.Lupin stated that the detailed inspection took place at the Somerset location this week, spanning from April 13 to April 17. The company confirmed that the inspection concluded with the issuance of the Form 483, which detailed three specific observations.The drug maker asserted its commitment to rectifying these observations and pledged to respond...